` ABUS (Arbutus Biopharma Corp) vs S&P 500 Comparison - Alpha Spread

ABUS
vs
S&P 500

Over the past 12 months, ABUS has outperformed S&P 500, delivering a return of +24% compared to the S&P 500's +15% growth.

Stocks Performance
ABUS vs S&P 500

Loading
ABUS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ABUS vs S&P 500

Loading
ABUS
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABUS vs S&P 500

Loading
ABUS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Arbutus Biopharma Corp vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Arbutus Biopharma Corp
Glance View

Market Cap
796.2m USD
Industry
Biotechnology

Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).

ABUS Intrinsic Value
0.25 USD
Overvaluation 94%
Intrinsic Value
Price
Back to Top